Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2327-2338

  Avramis, Vassilios I ^a,b   Nandy, Partha ^a   Kwock, Richard ^a   Solorzano, Michelle M ^a   Mukherjee, Suman K ^a   Danenberg, Peter ^b   Cohen, Lewis J ^c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SANOFI   (France)

Author keywords

Apoptosis; bcl 2; Cytarabine; Fludarabine; p21 WAF 1; p53; Synergism; Taxotere

Indexed keywords

CYTARABINE; DNA; DNA FRAGMENT; DOCETAXEL; FLUDARABINE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; T CELL LEUKEMIA;

APOPTOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTARABINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; KINETICS; LEUKEMIA, T-CELL; MATHEMATICS; MITOSIS; MODELS, BIOLOGICAL; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 0031863812     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Gandhi V, Estey E, Keating MJ, Plunkett W: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11: 116-124, 1993.
2. Avramis VI, Wiersma S, Cheng A: Selective pharmacological synergism between F-ara-A and ara-C in human leukemis cells in vitro and in vivo. Proc Am Soc Clin Oncol 8: 215, 1989.
3. Avramis VI, Biener R, Krailo M: Biochemical pharmacology of high-dose cytosine arabinoside (HD-ara-C) in childhood acute leukemia. Cancer Res 47: 6786-6792, 1987.
4. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, Finklestein J, Reaman G, Hammond GD, Holcenberg JS: Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 50: 7226-7231, 1990.
5. Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH: Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the Children's Cancer Group. J Clin Oncol 15: 2780-2785, 1997.
6. Ramilo-Torno LV, Avramis VI: Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. Cancer Chemother Pharmacol 35: 191-199, 1995.
7. Nandy P, Periclou AP, Avramis VI: Synergistic combinations of nucleoside analog drugs with other drugs induce greater apoptosis in human leukemic T-cells. Nucleos Nucleot 16: 1315-1319, 1997.
8. White E: Life, death, and the pursuit of apoptosis. Genes and Dev 10: 1-15, 1996.
9. Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W: Incorporation of fludarabine and 1-ß-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase °: affinity, interaction, and consequences. Clin Cancer Res 3: 1347-1355, 1997.
10. Iwasaki H, Huang P, Keating MJ, Plunkett W: Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90: 270-278, 1997.
11. Nandy P, Avramis VI, and Periclou AP: Extent of apoptosis in leukemic cells is related to synergistic combination drug regimens. Proc Am Assoc Cancer Res 38: 321, Abstr. #2154, 1997.
12. R . Proc Am Soc Clin Oncol 16: 545a, Abstr. #1966, 1997.
13. Huang P, Robertson LE, Wright S, Plunkett W: High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res 1: 1005-1013, 1995.
14. Clark AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH: p53 dependenceofearly apoptotic and proliferative responses within the mouse intestinal epithelium following τ-irradiation. Oncogene 9: 1767-1773, 1994.
15. Fan S, EI-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Conno'r PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
16. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75: 805-816, 1993.
17. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
18. Avramis VI, Kwock R, Reaman G: Synergistic antileukemic activity of fludarabine+ ara-C+ paclitaxel (Taxol) combination regimen against human leukemia cell lines. Proc Am Assco Cancer Res 36: 296, 1759, 1995.
19. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre-S: Preclinical evaluation of docetaxel (Taxotere). Seminars In Oncology 22: 3-16, 1995.
20. Mogil RJ, Shi Y, Bissonnette RP, Bromley P, Yamaguchi I, Green DR: Roleof DNA fragmentation in T cell activation-induced apoptosis in vitro and in vivo. J Immunol 152: 1674-1683, 1994.
21. Lavelle F, Gueritte-Voegelein F, Guenard D: Taxotere: from yew's needles to clinical practice. Bulletin Du Cancer 80: 326-338, 1993.
22. Bissery MC, Vrignaud P, Lavelle F: Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Seminars In Oncology 22: 17-24, 1995.
23. Banerjee D, Lenz HJ, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Danenberg P, Benino JR: Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Differe 6: 1405-1413, 1995.
24. Nandy P, Lien EJ, Avramis VI: Antileukemic activity studies and cellular pharmacology of the analogues of 2-hydroxy-1H-isoindole-1,3-dione (HISD) alone and in combination with cytosine arabinoside (ara-C) against human leukemia cells CEM/0. Acta Oncologica 33: 953-961, 1994.
25. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
26. Matsubara K, Kubota M, Adachi S, Kuwakado K, Hirota H, Wakazono Y, Akiyama Y, Mikawa H: Different mode of cell death induced by calcium ionophore in human leukemia cell lines: Possible role of constitutive endonuclease. Exp Cell Res 210: 19-25, 1994.
27. Burton K: A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315-323, 1956.
28. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871, 1992.
29. Huang P, Plunkett W: Fludarabine-and gemcitabine-induced apoptosis: incolporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36: 181-188, 1995.
30. Cheng J, Hass M: Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10: 5502-5509, 1990.
31. O'Connor PM, Jackman J, Insoo B, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr A>J, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency os 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
32. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906, 1994.
33. R and microwave heating. Blood 90: 200b, Abstr #3627, 1997.
34. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K: High levels of p26BCL-2 oncoprotein retarded taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8: 1960-1969, 1994.
35. L. Proc Am Assoc Clin Oncol 16: 546a, 1969, 1997.
36. Chen X, Bargonetti J, Prives C: p53 through p21(WAF1/CIP1) induces cyclin Dl synthesis. Cancer Research 55: 4257-4263, 1995.
37. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
38. Martin S, Green DR: Protease activation during apoptosis: Death by a thousand cuts? Cell 82: 349-352, 1995.
39. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
40. Olvati ZN, Millman CL, Korsmeyer SJ: Bcl-2 heterdimerizes in vivo with a conserved homolog, Bax. that accelerates programmed cell death. Cell 74: 609-619, 1993.
41. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
42. Yang T, Kozopas K, Craig R: The intracellular distribution and pattern of expression of McI-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 128: 1173-1184, 1995.
43. Zamzami N, Susin A, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G: Mitochondrial control of nuclear apoptosis. J Exp Med 183: 1533-1544, 1996.
44. Liu X, Kim C, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. Cell 86: 147-157, 1996.
45. Peitsch MC, Polzar B, Stephan H, Crompton T, McDonald HR, Mannherz HG, Tschopp J: Characterization of the endogenous deoxyribonuclease involved in nudear DNA degradation during apoptosis (programmed cell death). EMBO J 12: 371-377, 1993.
46. Baffy G, Miyashita T, Williamson J, Reed J: Apoptosis is induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 265: 6511-6519, 1993.
47. Martin DS, Schwartz GK: Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncology Research 9: 1-5, 1997.
48. McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ, Lowe SC: bax-defiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci 94: 2345-2349, 1997.
49. Fu CH, Nandy P, Siegel SE, Avramis VI: Increase in the bcl-2 to p53 ratio in leukemic cells from patients (pts) is associated with relapsed lellkemia. Proc 8th Interl Congr Anti-Cancer Treat (ICACT), pp. 118, Abstr. #179, Paris France, 1998.